Fibroblast News and Research

RSS

Fibroblasts are connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.

ArQule reduces third quarter net loss to $6,394,000

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2010.

9 Nov 2010

Research on immune system may help develop improved vaccines for cancer

Researchers at the University of Cambridge hope to revolutionise cancer therapy after discovering one of the reasons why many previous attempts to harness the immune system to treat cancerous tumours have failed.

8 Nov 2010

Skin to blood transformation in the lab

In a new study scientists have successfully transformed human skin cells into blood without first being sent through a primordial, stem-cell-like state. The findings were published online in the journal Nature. Earlier work has shown that fibroblast cells from mouse skin, treated with the right cocktail of chemicals, can be transformed into neurons and heart muscle. This is a first with human cells.

7 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.

3 Nov 2010

Research indicates stroma tissue provides new drug target for treating pancreatic cancer

A project focusing on the scar tissue surrounding cancer tumours aims to provide new targets for drugs for treating pancreatic cancer, the fifth highest cause of cancer deaths in the UK.

26 Oct 2010

BioMarin announces BMN-111 program for treatment of achondroplasia

BioMarin Pharmaceutical Inc. today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 2011 and to initiate a Phase 1 clinical trial by the first quarter of 2012.

19 Oct 2010

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting

ArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) of ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, at the annual meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Top research papers on venous disease receive VDC Research Awards

The Venous Disease Coalition (VDC) presented the Coalition's second annual Research Awards to the top three research papers on venous disease published in 2009 at the organization's Seventh Annual Meeting in Alexandria, VA.

7 Oct 2010

Five Prime Therapeutics receives patent for lead oncology product

Five Prime Therapeutics, Inc. today announced it has been issued two patents, U.S. Patent No. 7,678,890 and European Patent No.1910542B1, with claims covering various engineered Fibroblast Growth Factor Receptor ("FGFR") fusion proteins, including composition of matter claims for its lead oncology product, FP-1039.

21 Sep 2010

AIAM offers Skin Sculpting Technique training with Dermasculpt smooth-tip microcannula

The latest trend among European doctors, a non-bruising & virtually painless injection technique for fillers using an FDA approved, FLEXIBLE smooth-tip 27G 1 ½" microcannula instead of a sharp needle has now made its way to this side of the Atlantic.

16 Sep 2010

Emergency physicians to present research studies at Research Forum 2010

The risks associated with boarding admitted patients in the emergency department – including patient mortality – as well as proposed solutions will be key themes of Scientific Assembly, the annual meeting of the American College of Emergency Physicians. In addition, emergency physicians will present more than 450 research studies during 2010 Research Forum, the premier, annual scientific research event focused on the latest advances in the practice of emergency medicine.

14 Sep 2010

Study establishes critical roles for cancer-causing Myc gene in stem cell biology

Stem cells might be thought of as trunks in the tree of life. All multi-cellular organisms have them, and they can turn into a dazzling variety other cells-kidney, brain, heart or skin, for example. One class, pluripotent stem cells, has the capacity to turn into virtually any cell type in the body, making them a focal point in the development of cell therapies, the conquering of age-old diseases or even regrowing defective body parts.

3 Sep 2010

Regenicin acquires worldwide exclusive license to know-how technology

Regenicin, Inc., a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").

18 Aug 2010

ArQule second-quarter net loss decreases to $8,227,000

ArQule, Inc. today announced its financial results for the second quarter of 2010.

5 Aug 2010

Exposure of mBM-MSCs to VPA increases hepatic differentiation

Recent studies suggest that MSCs possess a greater differentiation potential than once thought and several hepatic differentiation protocols from bone marrow cells have been established. However, the incidence of bone marrow-derived hepatocytes was low. Moreover, a long culture period is needed in most cases.

31 Jul 2010

Kyowa Hakko Kirin initiates Phase 2 trial of ARQ 197 for gastric cancer: ArQule

ArQule, Inc. today announced the initiation of a Phase 2, single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin, its exclusive licensee for the development and commercialization of ARQ 197 in the Asian territory consisting of Japan, China (including Hong Kong), South Korea and Taiwan. Initiation of this trial will trigger a $5 million milestone payment to ArQule from Kyowa Hakko Kirin.

28 Jul 2010

Mount Sinai Hospital researchers discover new insights into genesis of stem cells

Mount Sinai Hospital researchers including Drs. Andras Nagy and Jeff Wrana have discovered new insights into the genesis of stem cells, which will improve the efficiency of stem cell creation for use in tissue regeneration and in the development of new drugs.

3 Jul 2010

Individual cells react differently to complex signals: Study

Using new technology that allows scientists to monitor how individual cells react in the complex system of cell signaling, Stanford University researchers have uncovered a much larger spectrum of differences between each cell than ever seen before.

29 Jun 2010